Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.

Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D.

J Biol Chem. 2006 Sep 29;281(39):29105-19. Epub 2006 Aug 3.

2.

Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.

Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H.

J Virol. 2006 Aug;80(15):7645-57.

3.

Conformation of polypyrimidine tract binding protein in solution.

Petoukhov MV, Monie TP, Allain FH, Matthews S, Curry S, Svergun DI.

Structure. 2006 Jun;14(6):1021-7.

4.
5.

Modular structure of solubilized human apolipoprotein B-100. Low resolution model revealed by small angle neutron scattering.

Johs A, Hammel M, Waldner I, May RP, Laggner P, Prassl R.

J Biol Chem. 2006 Jul 14;281(28):19732-9. Epub 2006 May 16.

6.

Monomeric APOBEC3G is catalytically active and has antiviral activity.

Opi S, Takeuchi H, Kao S, Khan MA, Miyagi E, Goila-Gaur R, Iwatani Y, Levin JG, Strebel K.

J Virol. 2006 May;80(10):4673-82.

7.

APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.

Chelico L, Pham P, Calabrese P, Goodman MF.

Nat Struct Mol Biol. 2006 May;13(5):392-9. Epub 2006 Apr 23.

PMID:
16622407
8.
9.

Structural basis of cellulosome efficiency explored by small angle X-ray scattering.

Hammel M, Fierobe HP, Czjzek M, Kurkal V, Smith JC, Bayer EA, Finet S, Receveur-Bréchot V.

J Biol Chem. 2005 Nov 18;280(46):38562-8. Epub 2005 Sep 12.

10.

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC.

Nature. 2005 May 5;435(7038):108-14. Epub 2005 Apr 13. Retraction in: Nature. 2010 Jul 8;466(7303):276.

PMID:
15829920
11.
12.

Complementary function of the two catalytic domains of APOBEC3G.

Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR.

Virology. 2005 Mar 15;333(2):374-86.

13.

Structure of human cytidine deaminase bound to a potent inhibitor.

Chung SJ, Fromme JC, Verdine GL.

J Med Chem. 2005 Feb 10;48(3):658-60.

PMID:
15689149
14.

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM.

Curr Biol. 2005 Jan 26;15(2):166-70.

15.

The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1.

Xie K, Sowden MP, Dance GS, Torelli AT, Smith HC, Wedekind JE.

Proc Natl Acad Sci U S A. 2004 May 25;101(21):8114-9. Epub 2004 May 17.

16.

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Yu Q, König R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR.

Nat Struct Mol Biol. 2004 May;11(5):435-42. Epub 2004 Apr 18.

PMID:
15098018
17.

HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Stopak K, de Noronha C, Yonemoto W, Greene WC.

Mol Cell. 2003 Sep;12(3):591-601.

18.

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR.

Cell. 2003 Jul 11;114(1):21-31.

19.

DNA deamination mediates innate immunity to retroviral infection.

Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH.

Cell. 2003 Jun 13;113(6):803-9. Erratum in: Cell. 2004 Feb 20;116(4):629.

20.

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D.

Nature. 2003 Jul 3;424(6944):99-103. Epub 2003 May 28.

PMID:
12808466
Items per page

Supplemental Content

Write to the Help Desk